Anti-Human RSV (Palivizumab Biosimilar)
Catalog #500045
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500045 | 1 mg | $200.00 | ||
| 500045 | 5 mg | $600.00 | ||
| 500045 | 20 mg | $1,250.00 |
Product Details
Palivizumab is a humanized monoclonal antibody (IgG1) designed to provide passive immunity against respiratory syncytial virus (RSV). As a biosimilar to the FDA-approved therapeutic palivizumab, it specifically targets the RSV fusion (F) protein, preventing viral entry into host cells and reducing the risk of severe RSV infection. Palivizumab binds to the F protein of RSV, blocking its ability to mediate viral fusion with the host cell membrane. This prevents viral replication and the spread of infection, making it a valuable tool for RSV research and therapeutic development.
Specifications
| Clone | Palivizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Respiratory Syncytial Virus F protein |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |